Recent clinical guidelines advocate for a diminished reliance on GnRH/Gonadotropin-releasing hormone analog (GnRHa) stimulation tests, instead prioritizing basal LH as a trustworthy biochemical marker for CPP diagnosis (22). This evidence concerns the gene PLOD1 and central precocious puberty.